Cutaneous  ||| S:0 E:10 ||| JJ
metastases  ||| S:10 E:21 ||| NN
from  ||| S:21 E:26 ||| IN
breast  ||| S:26 E:33 ||| JJ
carcinoma ||| S:33 E:42 ||| NN
:  ||| S:42 E:44 ||| :
calretinin  ||| S:44 E:55 ||| JJ
expression  ||| S:55 E:66 ||| NN
and  ||| S:66 E:70 ||| CC
estrogen ||| S:70 E:78 ||| NN
,  ||| S:78 E:80 ||| ,
progesterone  ||| S:80 E:93 ||| NN
and  ||| S:93 E:97 ||| CC
Her2 ||| S:97 E:101 ||| CD
/ ||| S:101 E:102 ||| CD
neu  ||| S:102 E:106 ||| JJ
status  ||| S:106 E:113 ||| NN
of  ||| S:113 E:116 ||| IN
the  ||| S:116 E:120 ||| DT
metastases ||| S:120 E:130 ||| NN
,  ||| S:130 E:132 ||| ,
compared  ||| S:132 E:141 ||| VBN
to  ||| S:141 E:144 ||| TO
primary  ||| S:144 E:152 ||| JJ
cutaneous  ||| S:152 E:162 ||| JJ
apocrine  ||| S:162 E:171 ||| JJ
tumors  ||| S:171 E:178 ||| NNS
Recently ||| S:178 E:186 ||| RB
,  ||| S:186 E:188 ||| ,
it  ||| S:188 E:191 ||| PRP
has  ||| S:191 E:195 ||| VBZ
been  ||| S:195 E:200 ||| VBN
demonstrated  ||| S:200 E:213 ||| VBN
how  ||| S:213 E:217 ||| WRB
apocrine  ||| S:217 E:226 ||| JJ
glands ||| S:226 E:232 ||| NN
,  ||| S:232 E:234 ||| ,
as  ||| S:234 E:237 ||| RB
well  ||| S:237 E:242 ||| RB
as  ||| S:242 E:245 ||| IN
several  ||| S:245 E:253 ||| JJ
cutaneous  ||| S:253 E:263 ||| JJ
apocrine  ||| S:263 E:272 ||| JJ
tumors ||| S:272 E:278 ||| NNS
,  ||| S:278 E:280 ||| ,
do  ||| S:280 E:283 ||| VBP
not  ||| S:283 E:287 ||| RB
express  ||| S:287 E:295 ||| VB
calretinin ||| S:295 E:305 ||| NNS
.  ||| S:305 E:307 ||| .
In  ||| S:307 E:310 ||| IN
the  ||| S:310 E:314 ||| DT
current  ||| S:314 E:322 ||| JJ
report ||| S:322 E:328 ||| NN
,  ||| S:328 E:330 ||| ,
we  ||| S:330 E:333 ||| PRP
studied  ||| S:333 E:341 ||| VBD
calretinin  ||| S:341 E:352 ||| JJ
immunoexpression  ||| S:352 E:369 ||| NN
in  ||| S:369 E:372 ||| IN
33  ||| S:372 E:375 ||| CD
cases  ||| S:375 E:381 ||| NNS
of  ||| S:381 E:384 ||| IN
cutaneous  ||| S:384 E:394 ||| JJ
metastases  ||| S:394 E:405 ||| NN
of  ||| S:405 E:408 ||| IN
ductal  ||| S:408 E:415 ||| JJ
breast  ||| S:415 E:422 ||| NN
carcinoma ||| S:422 E:431 ||| NN
,  ||| S:431 E:433 ||| ,
as  ||| S:433 E:436 ||| RB
well  ||| S:436 E:441 ||| RB
as  ||| S:441 E:444 ||| RB
in  ||| S:444 E:447 ||| IN
seven  ||| S:447 E:453 ||| CD
primary  ||| S:453 E:461 ||| JJ
cutaneous  ||| S:461 E:471 ||| JJ
apocrine  ||| S:471 E:480 ||| JJ
tumors ||| S:480 E:486 ||| NNS
.  ||| S:486 E:488 ||| .
We  ||| S:488 E:491 ||| PRP
also  ||| S:491 E:496 ||| RB
tested  ||| S:496 E:503 ||| VBN
the  ||| S:503 E:507 ||| DT
hormonal  ||| S:507 E:516 ||| JJ
status  ||| S:516 E:523 ||| NN
of  ||| S:523 E:526 ||| IN
all  ||| S:526 E:530 ||| DT
cases  ||| S:530 E:536 ||| NNS
for  ||| S:536 E:540 ||| IN
estrogen  ||| S:540 E:549 ||| JJ
receptors  ||| S:549 E:559 ||| NNS
( ||| S:559 E:560 ||| -LRB-
ER ||| S:560 E:562 ||| NNP
) ||| S:562 E:563 ||| -RRB-
,  ||| S:563 E:565 ||| ,
progesterone  ||| S:565 E:578 ||| JJ
receptors  ||| S:578 E:588 ||| NNS
( ||| S:588 E:589 ||| -LRB-
PR ||| S:589 E:591 ||| NNP
) ||| S:591 E:592 ||| -RRB-
,  ||| S:592 E:594 ||| ,
and  ||| S:594 E:598 ||| CC
ERRB2 ||| S:598 E:603 ||| NNP
.  ||| S:603 E:605 ||| .
From  ||| S:605 E:610 ||| IN
the  ||| S:610 E:614 ||| DT
33  ||| S:614 E:617 ||| CD
metastases ||| S:617 E:627 ||| NN
,  ||| S:627 E:629 ||| ,
26  ||| S:629 E:632 ||| CD
( ||| S:632 E:633 ||| -LRB-
78.79 ||| S:633 E:638 ||| NNP
% ||| S:638 E:639 ||| NN
)  ||| S:639 E:641 ||| -RRB-
cases  ||| S:641 E:647 ||| NNS
were  ||| S:647 E:652 ||| VBD
calretinin-negative  ||| S:652 E:672 ||| JJ
and  ||| S:672 E:676 ||| CC
seven  ||| S:676 E:682 ||| CD
cases  ||| S:682 E:688 ||| NNS
expressed  ||| S:688 E:698 ||| VBD
the  ||| S:698 E:702 ||| DT
marker ||| S:702 E:708 ||| NN
.  ||| S:708 E:710 ||| .
Five  ||| S:710 E:715 ||| CD
( ||| S:715 E:716 ||| -LRB-
15.15 ||| S:716 E:721 ||| NNP
% ||| S:721 E:722 ||| NN
)  ||| S:722 E:724 ||| -RRB-
cases  ||| S:724 E:730 ||| NNS
were  ||| S:730 E:735 ||| VBD
triple-negative  ||| S:735 E:751 ||| JJ
( ||| S:751 E:752 ||| -LRB-
ER- ||| S:752 E:755 ||| NNP
,  ||| S:755 E:757 ||| ,
PR- ||| S:757 E:760 ||| NNP
,  ||| S:760 E:762 ||| ,
Herceptest- ||| S:762 E:773 ||| NNP
) ||| S:773 E:774 ||| -RRB-
.  ||| S:774 E:776 ||| .
Of  ||| S:776 E:779 ||| IN
these  ||| S:779 E:785 ||| DT
five  ||| S:785 E:790 ||| CD
cases ||| S:790 E:795 ||| NNS
,  ||| S:795 E:797 ||| ,
three  ||| S:797 E:803 ||| CD
cases  ||| S:803 E:809 ||| NNS
were  ||| S:809 E:814 ||| VBD
calretinin+  ||| S:814 E:826 ||| CD
and  ||| S:826 E:830 ||| CC
two  ||| S:830 E:834 ||| CD
cases  ||| S:834 E:840 ||| NNS
were  ||| S:840 E:845 ||| VBD
calretinin- ||| S:845 E:856 ||| JJ
.  ||| S:856 E:858 ||| .
Three  ||| S:858 E:864 ||| CD
out  ||| S:864 E:868 ||| IN
of  ||| S:868 E:871 ||| IN
the  ||| S:871 E:875 ||| DT
seven  ||| S:875 E:881 ||| CD
cases  ||| S:881 E:887 ||| NNS
that  ||| S:887 E:892 ||| WDT
expressed  ||| S:892 E:902 ||| VBD
calretinin  ||| S:902 E:913 ||| RB
were  ||| S:913 E:918 ||| VBD
triple-negative ||| S:918 E:933 ||| JJ
.  ||| S:933 E:935 ||| .
From  ||| S:935 E:940 ||| IN
the  ||| S:940 E:944 ||| DT
seven  ||| S:944 E:950 ||| CD
primary  ||| S:950 E:958 ||| JJ
cutaneous  ||| S:958 E:968 ||| JJ
apocrine  ||| S:968 E:977 ||| JJ
tumors ||| S:977 E:983 ||| NNS
,  ||| S:983 E:985 ||| ,
only  ||| S:985 E:990 ||| RB
one  ||| S:990 E:994 ||| CD
showed  ||| S:994 E:1001 ||| VBD
focal  ||| S:1001 E:1007 ||| JJ
expression  ||| S:1007 E:1018 ||| NN
of  ||| S:1018 E:1021 ||| IN
calretinin ||| S:1021 E:1031 ||| NN
,  ||| S:1031 E:1033 ||| ,
and  ||| S:1033 E:1037 ||| CC
six  ||| S:1037 E:1041 ||| CD
of  ||| S:1041 E:1044 ||| IN
them  ||| S:1044 E:1049 ||| PRP
showed  ||| S:1049 E:1056 ||| VBD
a  ||| S:1056 E:1058 ||| DT
triple-negative  ||| S:1058 E:1074 ||| JJ
immunophenotype ||| S:1074 E:1089 ||| NN
.  ||| S:1089 E:1091 ||| .
Only  ||| S:1091 E:1096 ||| RB
the  ||| S:1096 E:1100 ||| DT
ER+ ||| S:1100 E:1103 ||| NNP
,  ||| S:1103 E:1105 ||| ,
PR+  ||| S:1105 E:1109 ||| CD
case  ||| S:1109 E:1114 ||| NN
showed  ||| S:1114 E:1121 ||| VBD
morphologic  ||| S:1121 E:1133 ||| JJ
features  ||| S:1133 E:1142 ||| NNS
on  ||| S:1142 E:1145 ||| IN
an  ||| S:1145 E:1148 ||| DT
in  ||| S:1148 E:1151 ||| FW
situ  ||| S:1151 E:1156 ||| FW
apocrine  ||| S:1156 E:1165 ||| FW
carcinoma ||| S:1165 E:1174 ||| FW
.  ||| S:1174 E:1176 ||| .
We  ||| S:1176 E:1179 ||| PRP
concluded  ||| S:1179 E:1189 ||| VBD
that  ||| S:1189 E:1194 ||| IN
our  ||| S:1194 E:1198 ||| PRP$
findings  ||| S:1198 E:1207 ||| NNS
support  ||| S:1207 E:1215 ||| VBP
the  ||| S:1215 E:1219 ||| DT
value  ||| S:1219 E:1225 ||| NN
of  ||| S:1225 E:1228 ||| IN
calretinin  ||| S:1228 E:1239 ||| NN
in  ||| S:1239 E:1242 ||| IN
the  ||| S:1242 E:1246 ||| DT
differential  ||| S:1246 E:1259 ||| JJ
diagnosis  ||| S:1259 E:1269 ||| NN
between  ||| S:1269 E:1277 ||| IN
a  ||| S:1277 E:1279 ||| DT
metastasis  ||| S:1279 E:1290 ||| NN
from  ||| S:1290 E:1295 ||| IN
breast  ||| S:1295 E:1302 ||| JJ
carcinoma  ||| S:1302 E:1312 ||| NN
into  ||| S:1312 E:1317 ||| IN
the  ||| S:1317 E:1321 ||| DT
skin  ||| S:1321 E:1326 ||| NN
and  ||| S:1326 E:1330 ||| CC
a  ||| S:1330 E:1332 ||| DT
primary  ||| S:1332 E:1340 ||| JJ
cutaneous  ||| S:1340 E:1350 ||| FW
apocrine  ||| S:1350 E:1359 ||| FW
carcinoma  ||| S:1359 E:1369 ||| FW
( ||| S:1369 E:1370 ||| -LRB-
CAC ||| S:1370 E:1373 ||| NNP
) ||| S:1373 E:1374 ||| -RRB-
,  ||| S:1374 E:1376 ||| ,
especially  ||| S:1376 E:1387 ||| RB
in  ||| S:1387 E:1390 ||| IN
triple-negative  ||| S:1390 E:1406 ||| JJ
cases ||| S:1406 E:1411 ||| NNS
.  ||| S:1411 E:1413 ||| .
However ||| S:1413 E:1420 ||| RB
,  ||| S:1420 E:1422 ||| ,
hormonal  ||| S:1422 E:1431 ||| JJ
markers  ||| S:1431 E:1439 ||| NN
plus  ||| S:1439 E:1444 ||| CC
calretinin  ||| S:1444 E:1455 ||| NNS
would  ||| S:1455 E:1461 ||| MD
not  ||| S:1461 E:1465 ||| RB
be  ||| S:1465 E:1468 ||| VB
sufficient  ||| S:1468 E:1479 ||| JJ
to  ||| S:1479 E:1482 ||| TO
discriminate  ||| S:1482 E:1495 ||| VB
between  ||| S:1495 E:1503 ||| IN
both  ||| S:1503 E:1508 ||| DT
diagnostic  ||| S:1508 E:1519 ||| JJ
possibilities ||| S:1519 E:1532 ||| NNS
,  ||| S:1532 E:1534 ||| ,
and  ||| S:1534 E:1538 ||| CC
they  ||| S:1538 E:1543 ||| PRP
are  ||| S:1543 E:1547 ||| VBP
probably  ||| S:1547 E:1556 ||| RB
better  ||| S:1556 E:1563 ||| RBR
used  ||| S:1563 E:1568 ||| VBN
when  ||| S:1568 E:1573 ||| WRB
integrated  ||| S:1573 E:1584 ||| VBN
in  ||| S:1584 E:1587 ||| IN
a  ||| S:1587 E:1589 ||| DT
wide  ||| S:1589 E:1594 ||| JJ
immunohistochemical  ||| S:1594 E:1614 ||| JJ
panel ||| S:1614 E:1619 ||| NN
.  ||| S:1619 E:1621 ||| .
